SCHEMBL23112760

SCHEMBL23112760

CCCCOC(=O)N1CC(Cl)(c2ccc(F)cc2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.42
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HRH2 P25021 2/20 0.41
HRH1 P35367 2/20 0.41
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
OPRM1 P35372 1/20 0.38
BCHE P06276 1/20 0.38
RORC P51449 1/20 0.37
FAAH O00519 1/20 0.37
MAPK1 P28482 1/20 0.37
HTR7 P34969 1/20 0.36
TSHR P16473 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MMP1 P03956 1/20 0.36
MMP9 P14780 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23112637 0.86 LMNA (0.43) LMNAPOLBSMN1; SMN2HRH2HRH1
SCHEMBL23112618 0.85 LMNA (0.42) LMNAPOLBSMN1; SMN2HRH2HRH1
SCHEMBL23112518 0.80 LMNA (0.38) LMNAPOLBSMN1; SMN2HRH2HRH1
SCHEMBL23382084 0.76 RORC (0.48) RORCMEN1KMT2AMMP13
SCHEMBL7425816 0.74 SMN1; SMN2 (0.45) LMNAPOLBSMN1; SMN2HRH2HRH1
SCHEMBL23112776 0.73 HRH2 (0.44) LMNAPOLBSMN1; SMN2HRH2HRH1
SCHEMBL23112895 0.73 HSD11B1 (0.39) POLBMEN1KMT2A
SCHEMBL30148517 0.72 OPRD1 (0.48) LMNAPOLBSMN1; SMN2OPRD1OPRK1
SCHEMBL23112361 0.72 HRH2 (0.43) LMNAPOLBSMN1; SMN2HRH2HRH1
SCHEMBL16230841 0.71 LMNA (0.56) LMNAPOLBSMN1; SMN2HRH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324865-A1 SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-10-13 US disclosed
WO-2021094210-A1 SUBSTITUTED PYRAZINE CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN EP3 RECEPTOR ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2021-05-20 WO disclosed
WO-2021094209-A1 SUBSTITUTED PYRROLO TRIAZINE CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN EP3 RECEPTOR ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2021-05-20 WO disclosed
EP-3793559-A1 SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES Bayer Aktiengesellschaft (DE) 2021-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324865-A1 SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES QDPR, SIRT5, PDXK LMNA 1734/4885POLB 3110/4885SMN1; SMN2 3131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.